SCHEMBL3016697

SCHEMBL3016697

O=S(=O)(c1ccc(Cl)c(Cl)c1)N1CCN(c2nc(-c3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.66
ALDH1A1 P00352 3/20 0.66
L3MBTL1 Q9Y468 1/20 0.66
AR P10275 1/20 0.63
MAPT P10636 4/20 0.56
USP2 O75604 1/20 0.56
RECQL P46063 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MAPK1 P28482 3/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
LMNA P02545 3/20 0.51
POLB P06746 1/20 0.51
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ABL1 P00519 1/20 0.46
HSD11B1 P28845 2/20 0.46
RAB9A P51151 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006075 0.94 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3015315 0.94 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL2999619 0.93 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3015927 0.93 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3018617 0.92 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3015955 0.92 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3006412 0.92 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3017674 0.91 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3012127 0.91 ALDH1A1 (0.64) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT
SCHEMBL3007814 0.91 SMN1; SMN2 (0.81) SMN1; SMN2ALDH1A1L3MBTL1ARMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.